Neuroendocrine Carcinoma of the Sigmoid Colon with Liver Metastases: A Case Report

Kazuhiro Aoki, Chihiro Ono, Hisanori Sugita, Yoshizumi Deguchi, Masayuki AndoNihon 2024 · DOI

Abstract

Neuroendocrine carcinoma (NEC) of the large intestine is a rare and highly aggressive malignancy with an extremely poor prognosis. We report the case of a 70-year-old male who presented with constipation and abdominal bloating. Diagnostic imaging revealed a sigmoid colon tumor and multiple liver metastases. Following a palliative transverse colostomy, an intraoperative biopsy confirmed the diagnosis of high-grade NEC. Despite the administration of five cycles of cisplatin and irinotecan (IP) therapy, the disease progressed rapidly, leading to the patient's death seven months after initial presentation. This case highlights the clinical challenges of managing metastatic NEC and the urgent need for standardized second-line treatment protocols.

Introduction

Neuroendocrine carcinomas (NEC) of the colon and rectum are rare, accounting for less than 1% of all colorectal cancers. Unlike well-differentiated neuroendocrine tumors (NET), NECs are characterized by high-grade cytological features, rapid proliferation, and early systemic metastasis. Due to their rarity, dedicated clinical trials are scarce, and treatment strategies are often adapted from small cell lung cancer (SCLC) protocols, typically involving platinum-based chemotherapy.

Case Presentation

A 70-year-old male presented with symptoms of sub-total bowel obstruction. Enhanced CT imaging identified a 70×50 mm primary tumor in the sigmoid colon and extensive bilobar liver metastases. To alleviate the obstruction and prepare for systemic therapy, a transverse colostomy was performed.

Diagnosis and Pathology

Intraoperative endoscopic biopsy was performed for definitive diagnosis. Histopathological examination using Hematoxylin and Eosin (HE) staining revealed atypical cells arranged in solid nests. Immunohistochemical (IHC) analysis was critical in confirming the neuroendocrine origin and high-grade nature of the tumor:

  • Ki-67 Index: >80%, indicating an extremely high rate of cell proliferation.
  • Synaptophysin: Positive staining confirmed neuroendocrine differentiation.
  • CK8/18: Positive staining was observed.

Based on these findings and the 2019 WHO classification, the tumor was diagnosed as a high-grade neuroendocrine carcinoma.

Histopathological and immunohistochemical findings: (A) HE staining, (B) Ki-67 index >80%, (C) Synaptophysin positive, (D) CK8/18 positive.

Clinical Course and Treatment

Following the "Pancreatico-Gastrointestinal Neuroendocrine Neoplasm Clinical Practice Guidelines," the patient was initiated on IP therapy (Irinotecan + Cisplatin). The regimen was administered in 4-week cycles to balance therapeutic efficacy with the patient's performance status and quality of life (QoL).

The patient completed five courses of IP therapy. While the disease was initially classified as stable (SD), tumor markers (CEA and CA19-9) began to rise sharply after 180 days. Subsequent imaging confirmed disease progression. Due to declining renal function (creatinine clearance <40 ml/min), chemotherapy was discontinued. The patient transitioned to palliative care and passed away 221 days after his first visit.

Clinical course graph illustrating the administration of CPT-11 (Irinotecan) + CDDP (Cisplatin) and the corresponding rise in tumor markers CEA and CA19-9 over 210 days.

Discussion

This case underscores the aggressive nature of colorectal NEC. Despite an initial period of stabilization, the tumor eventually bypassed the platinum-based regimen. A significant clinical hurdle identified in this case is the lack of established second-line therapies once first-line platinum agents fail or become contraindicated due to toxicity (such as renal impairment).

The decision to prioritize QoL by adjusting the chemotherapy schedule allowed the patient to remain at home for the majority of his remaining months. However, the overall survival of approximately seven months aligns with the poor outcomes reported in existing literature for metastatic NEC, where survival rarely exceeds one year.

Conclusion

Metastatic neuroendocrine carcinoma of the sigmoid colon remains a therapeutic challenge with a dire prognosis. While platinum-based combinations like Irinotecan and Cisplatin are the current standard, they often provide only transient benefits. Further accumulation of clinical cases and the development of standardized second-line treatments are essential to improve outcomes for patients with this aggressive malignancy.

Summary updated

Abstract

症例は70歳代,男性.便秘,腹部膨満を主訴に受診し,腹部CTでS状結腸腫瘍,多発性肝腫瘍を認めた.切除不能進行大腸癌の診断で横行結腸人工肛門造設術を行い,術中大腸内視鏡での生検で神経内分泌癌(Neuroendocrine carcinoma:NEC)と診断した.膵・消化管神経内分泌腫瘍診療ガイドラインに基づき,イリノテカン+シスプラチン療法を導入した.計5コース行ったが病状は進行し初診より7カ月で原病死した.遠隔転移を伴う消化管NECは極めて予後不良で,抗腫瘍薬の選択については小細胞肺癌に準じたプラチナ系薬剤を含む併用療法が推奨される.現時点で薬剤選択に関しては2次治療含めて確立されたものはなく,症例の集積と検討が必要である.今回われわれは多発性肝転移を伴ったS状結腸神経内分泌癌に対し集学的治療を行った1例を経験したので報告する.
BibTeX
@inproceedings{aoki2024neuroendocrine,
  author = {Kazuhiro Aoki and Chihiro Ono and Hisanori Sugita and Yoshizumi Deguchi and Masayuki Ando},
  title = {{Neuroendocrine Carcinoma of the Sigmoid Colon with Liver Metastases: A Case Report}},
  booktitle = {Nihon},
  year = {2024},
  doi = {10.4030/jjcs.49.506},
}
Figure